Articles citing this paper
cfArticle2ecfc1291681887$funcTITLE@4e972113
Melyssa L. Grieve 
A and Brett M. Paterson A B C
+ Author Affiliations
- Author Affiliations
A School of Chemistry, Monash University, Clayton, Vic. 3800, Australia.
B Monash Biomedical Imaging, Monash University, Clayton, Vic. 3800, Australia.
C Corresponding author. Email: brett.paterson@monash.edu
Melyssa Grieve graduated from Monash University in 2019 with a Bachelor of Science – Advanced Research (Honours) majoring in genetics and chemistry. In 2020 she joined the group of Dr Brett Paterson at Monash University as a Ph.D. student working on developing chelators for use in radiopharmaceuticals.
|
Dr Brett Paterson is a graduate of the University of Melbourne where Professor Paul Donnelly supervised his Ph.D. studies. This was followed by post-doctoral research with Professor Donnelly and a Victorian Post-Doctoral Fellowship at King's College London with Professor Phil Blower. Dr Paterson returned to Australia and received a Discovery Early Career Research Award from the Australian Research Council, which he undertook at Monash University. Dr Paterson was a National Imaging Facility Fellow at Monash Biomedical Imaging and is currently Head of Radiochemistry at the Centre for Advanced Imaging, University of Queensland.
|
Australian Journal of Chemistry 75(2) 65-88 https://doi.org/10.1071/CH21184
Submitted: 2 August 2021 Accepted: 29 October 2021 Published: 7 December 2021
Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides
Morgan Katherine A.,
Rudd Stacey E.,
Noor Asif, Donnelly Paul S.
Chemical Reviews. 2023 123(20). p.12004
Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents
Winuprasith Thunnalin,
Koirala Pankaj,
McClements David J, Khomein Piyachai
International Journal of Nanomedicine. 2023 Volume 18 p.4449
Macrocyclic 1,2-Hydroxypyridinone-Based Chelators as Potential Ligands for Thorium-227 and Zirconium-89 Radiopharmaceuticals
Woods Joshua J.,
Cosby Alexia G.,
Wacker Jennifer N.,
Aguirre Quintana Luis M.,
Peterson Appie,
Minasian Stefan G., Abergel Rebecca J.
Inorganic Chemistry. 2023 62(50). p.20721
The Curies’ element: state of the art and perspectives on the use of radium in nuclear medicine
Franchi Sara,
Asti Mattia,
Di Marco Valerio, Tosato Marianna
EJNMMI Radiopharmacy and Chemistry. 2023 8(1).
Covalent labeling of immune cells
Rösner Lukas,
Konken Christian Paul,
Depke Dominic Alexej,
Rentmeister Andrea, Schäfers Michael
Current Opinion in Chemical Biology. 2022 68 p.102144
Bispidine Chelators for Radiopharmaceutical Applications with Lanthanide, Actinide, and Main Group Metal Ions
Kopp Ina,
Cieslik Patrick,
Anger Karl,
Josephy Thomas,
Neupert Lucca,
Velmurugan Gunasekaran,
Gast Michael,
Wadepohl Hubert,
Brühlmann Santiago Andrés,
Walther Martin,
Kopka Klaus,
Bachmann Michael,
Stephan Holger,
Kubeil Manja, Comba Peter
Inorganic Chemistry. 2023 62(50). p.20754
Alpha-Emitting Radionuclides: Current Status and Future Perspectives
Miederer Matthias,
Benešová-Schäfer Martina,
Mamat Constantin,
Kästner David,
Pretze Marc,
Michler Enrico,
Brogsitter Claudia,
Kotzerke Jörg,
Kopka Klaus,
Scheinberg David A., McDevitt Michael R.
Pharmaceuticals. 2024 17(1). p.76
Advances in targeted alpha therapy of cancer
Sathekge Mike, Morgenstern Alfred
European Journal of Nuclear Medicine and Molecular Imaging. 2024 51(5). p.1205
